Comirnaty COVID-19 mRNA vaccines (tozinameran) (tozinameran / famtozinameran) | Pfizer Medical Information

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

Comirnaty COVID-19 mRNA vaccines Quick Search

Pharmacovigilance website

You can report an adverse related to the Pfizer-BioNTech COVID-19 Vaccine, either on the gouvernmental website https://signalement.social-sante.gouv.fr, or on the Safety Pfizer website at www.pfizersafetyreporting.com.
A NSM information on COVID-19 vaccines

Information from the National health and medications agency (ANSM) regarding COVID-19 vaccines are available at: www.ansm.sante.fr/Dossiers/COVID-19-Vaccins
Guidance and instructions for healthcare professionals on how to use the Comirnaty vaccine

Access safety data sheets, instructions on how to use the vaccine, guidance for shipping, handling, storage or administration, on the website  www.comirnatyglobal.com.
HAS Recommendations

In the context of Covid-19 pandemic, you can access the work and recommendations of the Haute Autorité de Santé (HAS)
Resources

The last version of the Summary of Product Characteristics (SPC) for COMIRNATY forms can be accessed below:
Formulations for adults and adolescents ≥12 years:

15/15 μg/dose tozinameran/ famtozinameran (Original/Omicron BA.4-5), ready-to-use, grey cap: SPC
30 μg/dose tozinameran, ready-to-use, grey cap: SPC
30 μg/dose tozinameran, dilution required, purple cap: SPC

Pediatric formulations:

For infants and children aged 6 months to 4 years: 3 μg/dose tozinameran, dilution required, maroon cap: SPC
For children aged 5 to 11 years: 10 μg/dose tozinameran, dilution required, orange cap: SPC

Did you find an answer to your question? Yes No

Didn’t find what you were looking for? Contact us.

Call 01 58 07 34 40^*

*Contact Medical Information. 09h - 18h Monday to Friday.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 vaccines, click the link below:
www.pfizersafetyreporting.com

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please contact Pfizer pharmacovigilance at [email protected].

Governmental website

You may also report adverse events online on the Ministry of Health’s website ‘Portail de signalement des événements sanitaires indésirables’ at https://signalement.social-sante.gouv.fr